<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05792059</url>
  </required_header>
  <id_info>
    <org_study_id>01-02/23</org_study_id>
    <nct_id>NCT05792059</nct_id>
  </id_info>
  <brief_title>DevElopMent of Clinical PATHwaYs to the Diagnosis of Heart Failure With Preserved Ejection Fraction</brief_title>
  <acronym>EMPATHY-HF</acronym>
  <official_title>DevElopMent of Clinical PATHwaYs to the Diagnosis of Heart Failure With Preserved Ejection Fraction (EMPATHY-HF)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Medical Research Center for Therapy and Preventive Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Medical Research Center for Therapy and Preventive Medicine</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prevalence of heart failure with preserved ejection fraction (HFpEF) continues to increase in&#xD;
      the developed world, likely because of the increasing life expectancy and an increasing&#xD;
      number of elderly patients.&#xD;
&#xD;
      Transthoracic echocardiography is essential for the diagnosis of HFpEF according to the&#xD;
      current guidelines. The HFA-PEFF and H2FPEF diagnostic algorithms rely on clinical&#xD;
      characteristics and echocardiography findings that indicate the presence of diastolic&#xD;
      dysfunction.&#xD;
&#xD;
      These diagnostic algorithms are not applicable in remote areas where expert echocardiography&#xD;
      cannot be performed due to the absence of modern ultrasound systems and lack of qualified&#xD;
      specialists. Therefore, it is important to develop an algorithm to evaluate pre-test&#xD;
      probability of HFpEF without echocardiographic markers, so it can be easily used in the&#xD;
      primary outpatient care setting by any specialist.&#xD;
&#xD;
      The aim of this study is to find the associations between clinical and epidemiological&#xD;
      characteristics and changes of intracardiac hemodynamics in patients with dyspnea and&#xD;
      decreased exercise tolerance.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 9, 2023</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>An increased of post-exercise E/e' ratio</measure>
    <time_frame>during diastolic stress test (baseline)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>An increased of post-exercise pulmonary artery systolic pressure (PASP)</measure>
    <time_frame>during diastolic stress test (baseline)</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Heart Failure With Preserved Ejection Fraction (HFpEF)</condition>
  <arm_group>
    <arm_group_label>patients with HFpEF</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>patients without HFpEF</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients complaining of shortness of breath, with two or more chronic&#xD;
        non-communicable diseases (patients with comorbidities)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients complaining of shortness of breath, with two or more chronic&#xD;
             non-communicable diseases (patients with comorbidities)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Morbid obesity;&#xD;
&#xD;
          -  Any chronic diseases in the stage of exacerbation and / or decompensation;&#xD;
&#xD;
          -  Systemic diseases, cancer;&#xD;
&#xD;
          -  Cardiac arrhythmias: persistent atrial fibrillation or paroxysmal atrial fibrillation&#xD;
             with frequent paroxysms;&#xD;
&#xD;
          -  History of myocardial infarction, stroke, heart failure with reduced ejection&#xD;
             fraction;&#xD;
&#xD;
          -  Storage diseases, hypertrophic cardiomyopathy, concentric hypertrophy;&#xD;
&#xD;
          -  Congenital and acquired heart defect;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Olga Dzhioeva</last_name>
    <phone>+7 (916) 614-18-21</phone>
    <email>odzhioeva@gnicpm.ru</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Medical Research Center for Therapy and Preventive Medicine</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olga Dzhioeva</last_name>
      <phone>+79166141821</phone>
      <email>odzhioeva@gnicpm.ru</email>
    </contact>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>April 2023</verification_date>
  <study_first_submitted>March 17, 2023</study_first_submitted>
  <study_first_submitted_qc>March 17, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">March 30, 2023</study_first_posted>
  <last_update_submitted>April 4, 2023</last_update_submitted>
  <last_update_submitted_qc>April 4, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

